These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26967369)

  • 1. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
    Günther T; Culler M; Schulz S
    Mol Endocrinol; 2016 Apr; 30(4):479-90. PubMed ID: 26967369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
    Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines.
    Kuzhikandathil EV; Yu W; Oxford GS
    Mol Cell Neurosci; 1998 Dec; 12(6):390-402. PubMed ID: 9888991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
    Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin activates two types of inwardly rectifying K+ channels in MIN-6 cells.
    Smith PA; Sellers LA; Humphrey PP
    J Physiol; 2001 Apr; 532(Pt 1):127-42. PubMed ID: 11283230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
    Cervia D; Fehlmann D; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
    Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
    Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
    Peverelli E; Olgiati L; Locatelli M; Magni P; Fustini MF; Frank G; Mantovani G; Beck-Peccoz P; Spada A; Lania A
    Cancer Lett; 2010 Feb; 288(2):170-6. PubMed ID: 19619936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects.
    Park S; Kamegai J; Kineman RD
    Neuroendocrinology; 2003 Sep; 78(3):163-75. PubMed ID: 14512709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
    Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
    Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA.
    Luque RM; Park S; Peng XD; Delgado E; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
    J Mol Endocrinol; 2004 Apr; 32(2):437-48. PubMed ID: 15072550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.